FORTREA HOLDINGS INC

FTRENASDAQ

🏆 #2038 by market capEarnings Nov 3 · PreUS Equity

$212.21▼ $7.41 (−3.49%)

Simulated price

🔔

Track FTRE

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 3.5%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$1.91B

Small Cap

📈Revenue Growth (YoY)

-2.1%

Declining

📊Gross Margin

19.3%

Thin

💵FCF Margin

8.3%

Moderate

⚖️P/S Ratio

0.7x

Cheap

Otter Score

Fair

No chart data available for FTRE.

Trading Snapshot

Day Range: $209.61 – $215.53
52-Week Range: $8.31 – $21.39
Volume: $5.51B
Avg Volume: $6.37B
Shares Outstanding: 95.1M
Next Earnings: Nov 30, 2026

Fundamentals Snapshot

Annual Revenue: $2.72B
Last Q Revenue: $678M
P/E Ratio: —
P/S Ratio: 0.7x
EPS (TTM): $-0.91
Dividend Yield: —
Dilution (1yr): +1.3%

Why Investors Own FTRE

✓High-growth profile — revenue up +13.5% YoY with expanding US Equity exposure.
✓Healthy economics — 40% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

FORTREA HOLDINGS INC

FTRE

Financial Trends

Revenue

$2.7B▲ +1.0% YoY

Gross Margin

15.6%▼ −21.1% YoY

Operating Income

−$31M▼ −81.1% YoY

Free Cash Flow

$88M▼ −62.8% YoY

Shares Outstanding

91.2M▲ +1.3% YoY

Net Cash

−$941M▲ +$139M YoY

StockOtter · stockotter.space

About FORTREA HOLDINGS INC

Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.

🦦